Document Detail

Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.
MedLine Citation:
PMID:  23325085     Owner:  NLM     Status:  MEDLINE    
Development of steroid dependency in patients with nephrotic syndrome may require a long-term multi-drug therapy at risk of drug toxicity and renal failure. Rituximab treatment reduces the steroid dosage and the need for immunosuppressive therapy in pediatric patients. Here we retrospectively analyze the efficacy and safety of rituximab in adult patients with steroid-dependent minimal change disease. To do this, we analyzed the outcome of all adult patients treated with rituximab for steroid-dependent minimal change nephrotic syndrome over a mean follow-up of 29.5 months (range 5.1-82 months). Seventeen patients with steroid-dependent or frequently relapsing minimal change nephrotic syndrome, unresponsive to several immunosuppressive medications, were treated with rituximab. Eleven patients had no relapses after rituximab infusion (mean follow-up 26.7 months, range 5.1-82 months) and nine of them were able to come off all other immunosuppressive drugs and steroids during follow-up. Six patients relapsed at least once after a mean time of 11.9 months (mean follow-up 34.5 months, range 16.9-50.1 months), but their immunosuppressive drug treatment could be stopped or markedly reduced during this time. No adverse events were recorded. Thus, rituximab is efficient and safe in adult patients suffering from severe steroid-dependent minimal change disease. Prospective randomized trials are needed to confirm this study.
Helene Munyentwali; Khedidja Bouachi; Vincent Audard; Philippe Remy; Philippe Lang; Rachid Mojaat; Georges Deschênes; Pierre M Ronco; Emmanuelle M Plaisier; Karine Y Dahan
Related Documents :
23001685 - Celecoxib does not affect the release of hyaluronic acid in end stage osteoarthritic jo...
12791115 - Does ketamine or magnesium affect posttonsillectomy pain in children?
22959565 - Approaching a paradigm shift: endoscopic ablation of lone atrial fibrillation on the be...
8971315 - Acupuncture and postoperative vomiting in day-stay paediatric patients.
23884495 - Photopneumatic therapy for the treatment of keratosis pilaris.
17240935 - The four dimensions of orthodontic diagnosis--part ii.
Publication Detail:
Type:  Journal Article     Date:  2013-01-16
Journal Detail:
Title:  Kidney international     Volume:  83     ISSN:  1523-1755     ISO Abbreviation:  Kidney Int.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-28     Completed Date:  2013-08-20     Revised Date:  2013-12-11    
Medline Journal Info:
Nlm Unique ID:  0323470     Medline TA:  Kidney Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  511-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal, Murine-Derived / adverse effects,  therapeutic use*
Antigens, CD19 / analysis
Antigens, CD20 / immunology*
Immunosuppressive Agents / therapeutic use
Middle Aged
Nephrosis, Lipoid / drug therapy*
Prednisone / therapeutic use*
Retrospective Studies
Reg. No./Substance:
0/Antibodies, Monoclonal, Murine-Derived; 0/Antigens, CD19; 0/Antigens, CD20; 0/Immunosuppressive Agents; 0/rituximab; VB0R961HZT/Prednisone
Comment In:
Kidney Int. 2013 Nov;84(5):1050   [PMID:  24172741 ]
Kidney Int. 2013 Nov;84(5):1049   [PMID:  24172738 ]
Kidney Int. 2013 Mar;83(3):343-5   [PMID:  23446250 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic k...
Next Document:  Human renal stem/progenitor cells repair tubular epithelial cell injury through TLR2-driven inhibin-...